Acute Hemodynamic Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Diastolic Heart Failure (DILATE-1)
暂无分享,去创建一个
S. Rosenkranz | Lothar Roessig | C. Lam | R. Steringer-Mascherbauer | D. Bonderman | I. Lang | P. Jansa | Andja Bojic | S. Unger | R. Frey | M. Ochan Kilama | I. Pretsch | C. Tufaro | A. Bojic | R. Steringer‐Mascherbauer | L. Roessig
[1] Volkmar Falk,et al. 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. , 2016, Revista espanola de cardiologia.
[2] H. Ghofrani,et al. Riociguat for Patients With Pulmonary Hypertension Caused by Systolic Left Ventricular Dysfunction: A Phase IIb Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Hemodynamic Study , 2013, Circulation.
[3] M. Humbert,et al. Riociguat for the treatment of pulmonary arterial hypertension. , 2013, The New England journal of medicine.
[4] Chen Wang,et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. , 2013, The New England journal of medicine.
[5] W. Paulus,et al. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. , 2013, Journal of the American College of Cardiology.
[6] Manesh R. Patel,et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. , 2013, JAMA.
[7] Yuhui Zhang,et al. Diastolic pulmonary vascular pressure gradient: a predictor of prognosis in "out-of-proportion" pulmonary hypertension. , 2013, Chest.
[8] D. Brutsaert,et al. Endothelial dysfunction: a pathophysiologic factor in heart failure with preserved ejection fraction. , 2012, Journal of the American College of Cardiology.
[9] S. Umemura,et al. Incremental prognostic significance of peripheral endothelial dysfunction in patients with heart failure with normal left ventricular ejection fraction. , 2012, Journal of the American College of Cardiology.
[10] Juerg Schwitter,et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2010, European journal of heart failure.
[11] J. Bronzwaer,et al. Low Myocardial Protein Kinase G Activity in Heart Failure With Preserved Ejection Fraction , 2012, Circulation.
[12] R. Nishimura,et al. Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy. , 2012, Journal of the American College of Cardiology.
[13] V. Roger,et al. Pulmonary pressures and death in heart failure: a community study. , 2012, Journal of the American College of Cardiology.
[14] L. Levin,et al. The Soluble Guanylyl Cyclase Activator YC-1 Increases Intracellular cGMP and cAMP via Independent Mechanisms in INS-1E Cells , 2011, Journal of Pharmacology and Experimental Therapeutics.
[15] Pál Pacher,et al. Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. , 2011, Circulation.
[16] P. Brouckaert,et al. sGC{alpha}1 mediates the negative inotropic effects of NO in cardiac myocytes independent of changes in calcium handling. , 2011, American journal of physiology. Heart and circulatory physiology.
[17] J. Stasch,et al. Riociguat for the treatment of pulmonary hypertension , 2011, Expert opinion on investigational drugs.
[18] J. Gardin,et al. Reference Values of Right Ventricular End‐Diastolic Area Defined by Ethnicity and Gender in a Young Adult Population: The CARDIA Study , 2011, Echocardiography.
[19] R. Arena,et al. Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction: A Target of Phosphodiesterase-5 Inhibition in a 1-Year Study , 2009, Circulation.
[20] Amir Lerman,et al. Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction. , 2010, Journal of the American College of Cardiology.
[21] J. Stasch,et al. Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models , 2010, Journal of hypertension.
[22] B. Borlaug,et al. Caveat medicus! Pulmonary hypertension in the elderly: a word of caution , 2010, European journal of heart failure.
[23] W. Kuebler,et al. Iloprost Inhalation Causes Lung Edema in Overperfused Heart Failure Lungs. , 2009, ATS 2009.
[24] N. Weissmann,et al. First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension , 2009, European Respiratory Journal.
[25] V. Roger,et al. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. , 2009, Journal of the American College of Cardiology.
[26] H. Ghofrani,et al. Soluble guanylate cyclase stimulation: an emerging option in pulmonary hypertension therapy , 2009, European Respiratory Review.
[27] J. Stasch,et al. NO-independent, haem-dependent soluble guanylate cyclase stimulators. , 2009, Handbook of experimental pharmacology.
[28] P. Vermeersch,et al. Gender-specific hypertension and responsiveness to nitric oxide in sGCalpha1 knockout mice. , 2008, Cardiovascular research.
[29] V. Roger,et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. , 2006, The New England journal of medicine.
[30] William Stewart,et al. Recommendations for chamber quantification. , 2006, European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology.
[31] Richard B Devereux,et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardio , 2005, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.
[32] T. Münzel,et al. Explaining the phenomenon of nitrate tolerance. , 2005, Circulation research.
[33] Stuart D Katz,et al. Vascular Endothelial Dysfunction and Mortality Risk in Patients With Chronic Heart Failure , 2005, Circulation.
[34] W. Gaasch,et al. Diastolic heart failure--abnormalities in active relaxation and passive stiffness of the left ventricle. , 2004, The New England journal of medicine.
[35] D. Kass,et al. Combined Ventricular Systolic and Arterial Stiffening in Patients With Heart Failure and Preserved Ejection Fraction: Implications for Systolic and Diastolic Reserve Limitations , 2003, Circulation.
[36] I. Palacios,et al. Coronary endothelial dysfunction in patients with acute-onset idiopathic dilated cardiomyopathy. , 1998, Journal of the American College of Cardiology.
[37] G. A. Rooke,et al. Work as a Correlate of Canine Left Ventricular Oxygen Consumption, and the Problem of Catecholamine Oxygen Wasting , 1982, Circulation research.